Ki-67 Immunostaining Proliferation Assay
Materials Required
Principle
Ki-67 immunostaining measures the growth fraction of a cell population by detecting Ki-67, a nuclear antigen present in proliferating cells and absent in quiescent G0 cells[1][2]. The readout is the percentage of Ki-67-positive nuclei among total counted cells, commonly called the Ki-67 labeling index or proliferation index[2][3].
MCE has not independently verified the accuracy of these methods. They are for reference only.
Experimental Materials
Reagents and chemicals
• Fixed cultured cells or formalin-fixed paraffin-embedded tissue sections can be used for Ki-67 immunostaining[3][4].• Blocking solution, wash buffer, chromogenic substrate for immunohistochemistry, or fluorescence-compatible mounting medium for immunofluorescence are used according to the selected detection format[3][4].
Antibodies, probes, dyes, or kits
• Anti-Ki-67 antibodies, including MIB-1 and other validated clones, are used to detect Ki-67-positive nuclei[3][5].• Hematoxylin or nuclear fluorescent counterstains are used to identify total nuclei for proliferation-index calculation[3][4].
Equipment and instruments
• Brightfield microscopy is used for chromogenic Ki-67 immunohistochemistry, and fluorescence microscopy or digital image analysis can be used for fluorescent Ki-67 staining[3][4][6].• Manual counting, semi-automated image analysis, or standardized digital scoring can be used, but scoring method must be kept consistent within an experiment[4][6].
Experimental Procedure
Preparation Steps
• Prepare fixed cells or tissue sections and select a validated anti-Ki-67 antibody and detection system appropriate for the sample type[3][5].• Include a proliferative positive-control tissue or cell sample and a no-primary-antibody or isotype-control condition to evaluate staining specificity and background[3][4].
Operation Steps
• Perform fixation-compatible Ki-67 immunostaining by blocking nonspecific binding, incubating with anti-Ki-67 antibody, applying the appropriate secondary detection reagent, counterstaining nuclei, and mounting the sample for imaging[3][4].• For paraffin tissue sections, antigen retrieval and standardized fixation are important because preanalytical and analytical variation can affect Ki-67 staining and scoring reproducibility[3][7].
Data Acquisition and Analysis
• Count Ki-67-positive nuclei and total nuclei in predefined fields, then calculate the Ki-67 labeling index as positive nuclei divided by total counted nuclei[2][3].• In heterogeneous tumors, global scoring across fields reflecting the observed staining heterogeneity is more reproducible than selecting only the highest hot spot in a multicenter breast cancer scoring study[4].
• Report the scoring method, number of cells or fields counted, antibody clone, sample type, and positivity threshold because Ki-67 interpretation is sensitive to methodological variation[3][4][7].
Troubleshooting
Problem: High interobserver or interfield variability.
• Possible Cause: Ki-67 staining can be heterogeneous and scoring practice varies between observers.• Literature-supported Solution: Use a predefined scoring rule and global field selection that reflects tumor heterogeneity rather than an informal hot-spot-only approach[4][7].
Problem: Weak or inconsistent nuclear staining.
• Possible Cause: Fixation, antigen retrieval, antibody clone, or detection conditions may differ between samples.• Literature-supported Solution: Standardize preanalytical and analytical conditions and include positive-control tissue in each staining run[3][7].
Problem: Ki-67 index is difficult to interpret biologically.
• Possible Cause: Ki-67 marks cycling cells but does not directly measure DNA synthesis rate or mitosis alone.• Literature-supported Solution: Interpret Ki-67 as a growth-fraction marker and, when needed, validate with complementary assays such as EdU/BrdU incorporation or phospho-histone H3 staining[1][2][8].
References:
- [1]. Gerdes J, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133(4):1710-1715. [Content Brief]
- [2]. Scholzen T, et al. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182(3):311-322. [Content Brief]
- [3]. Dowsett M, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst. 2011;103(22):1656-1664. [Content Brief]
- [4]. Leung SCY, Nielsen TO, Zabaglo LA, Arun I, Badve SS, Bane AL, Bartlett JMS, Borgquist S, Chang MC, Dodson A, et al. Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration. Histopathology. 2019;75(2):225-235. [Content Brief]
- [5]. Vörös A, et al. An intra- and interobserver reproducibility analysis of the Ki-67 proliferation marker assessment on core biopsies of breast cancer patients and its potential clinical implications. Pathobiology. 2013;80(3):111-118. [Content Brief]
- [6]. Fernezlian S, et al. A semi-automated microscopic image analysis method for scoring Ki-67 nuclear immunostaining. Braz J Med Biol Res. 2023;56:e12922. [Content Brief]
- [7]. Nielsen TO, et al. Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2021;113(7):808-819. [Content Brief]
- [8]. Isola J, et al. Evaluation of cell proliferation in breast carcinoma. Comparison of Ki-67 immunohistochemical study, DNA flow cytometric analysis, and mitotic count. Cancer. 1990;65(5):1180-1184. [Content Brief]
LinkedIn
Researchgate
Instagram
X
Facebook
WhatsApp
Reddit
Mail